A New Category of Antiviral Design
Decoy Therapeutics is a biotechnology company advancing a new way to treat viral disease.
The company is pioneering Designable Multi-Antivirals (DMAVs), a new category of antivirals engineered to target shared viral mechanisms. By focusing on mechanisms conserved across viruses, DMAVs are designed to enable a single multi-use drug to work against multiple viral threats, moving beyond the traditional one-virus, one-drug model.
DMAVs are built on Decoy’s proprietary peptide conjugate platform, IMP³ACT. The platform integrates AI-enabled design with rapid synthesis and manufacturing, creating a repeatable and scalable approach to antiviral development. This architecture is intended to support faster iteration and broader application across viral families while maintaining clinical rigor.
Decoy’s lead programs are focused on respiratory viruses that continue to drive significant health and societal disruption worldwide. By designing antivirals that reflect how viral threats behave in the real world, the company aims to expand what is possible in prevention and treatment.
Our website is currently being updated to reflect our evolving strategy and platform.
For partnership, investor, or media inquiries, please contact:
contact@decoytx.com
© 2026 Decoy Therapeutics
Supported By
Featured Press Releases
Pipeline
We are committed to innovation and patient-centric drug development.
Program
Indication
Discovery
Preclinical
Clinic
Pan-Coronavirus
Broad-acting Fusion Inhibitor
SARS-CoV-2 + all other human coronaviruses
Preclinical
Safe early intervention for 5M+ immune-compromised patients with minimal drug-drug interactions, unlike Paxlovid
Learn more
Pan-Coronavirus Inhibitor for Immunocompromised Patients:
- In the United States alone, over 10 million individuals are severely immunocompromised. These patients are at heightened risk of negative or life-threatening outcomes from coronaviruses, even in the era of endemic COVID-19.
- There are limited options for these patients. Antibody therapeutics, such as Evusheld, have not been able to keep up with viral evolution, and Paxlovid, a $2B+/year revenue drug, is limited in its usage because of significant interactions with other drugs that are highly prescribed in high-risk populations.
- Our lead program is a self-administered nasally inhaled pan-coronavirus fusion inhibitor that has shown in vitro efficacy against all known human coronaviruses, including all variants of COVID-19, and significant activity in multiple animal models. This self-administered nasal spray is expected to offer 8-24 hours of prophylactic protection, and to moderate disease severity when used post-infection.
Tripledemic
Broad-acting Fusion Inhibitor
Flu + COVID + RSV antiviral
Discovery
A single antiviral to treat the “big three” viruses that are responsible for 70+% of dangerous virally-driven lower respiratory tract infections
Learn more
Broad Respiratory Antiviral for Tripledemic (Flu/COVID/RSV):
- The “tripledemic” and related viruses are responsible for 70+% of virus-driven Lower Respiratory Tract Infections (LRTIs). According to the World Health Organization, LRTIs are the 4th leading cause of death globally and represent a major health burden for both healthy people and very large, high-risk populations including patients suffering from COPD, autoimmune disorders, chronic kidney disease diabetes, obesity, and the elderly.
- Employing the same mechanism of action and computational models developed in the pan-coronavirus program, we are exploiting highly-conserved structural similarities to design a single antiviral fusion inhibitor that will be effective against all the “tripledemic” and related viruses.
- We expect this inhaled, self-administered early intervention to be both a $15B+ commercial opportunity and a powerful global public health tool.
Meet the Team
Board of Directors
Scientific Advisors
Dan Kuritzkes
MD
Harriet Ryan Albee Professor of Medicine and Chief of Infectious Disease, Harvard Medical School
Marc B. Garnick
MD
Gorman Brothers Professor of Medicine,
Harvard Medical School & Beth Israel Medical Center
Special Advisor, US FDA
